Fourth Quarter Highlights
-
Net sales of $104.6 million; an increase of 7.6% over prior year on
a constant currency basis
-
Adjusted EBITDA of $19.3 million, or 18.4% of net sales
-
Stock repurchases of approximately 294,000 shares for $11.6 million
Fiscal Year 2015 Highlights
-
Net sales of $396.5 million; an increase of 2.4% over prior year on
a constant currency basis
-
Adjusted EBITDA of $60.7 million, or 15.3% of net sales
LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V. (NASDAQ:OFIX) today reported its financial
results for the fourth quarter and fiscal year ended December 31, 2015.
For the fourth quarter of 2015, net sales were $104.6 million, diluted
earnings per share from continuing operations was $0.11 and adjusted
diluted earnings per share from continuing operations was $0.28. For the
fiscal year of 2015, net sales were $396.5 million, diluted loss per
share from continuing operations was ($0.12) and adjusted diluted
earnings per share from continuing operations was $0.79.
"Our fourth quarter performance further demonstrates our momentum and
validates our strategy and the strength of our businesses. While we are
very pleased with the results in the quarter, we also believe there is
significant opportunity to continue to improve our performance going
forward. In 2016 we will maintain our focus on executing initiatives
that drive both top line growth and margin improvement," said Brad
Mason, President and Chief Executive Officer.
Fourth Quarter Financial Results
The following table provides net sales, net sales growth and constant
currency net sales growth by strategic business unit ("SBU") for the
three months ended December 31, 2015 and 2014:
|
|
|
|
Three Months Ended December 31,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Constant
|
|
|
|
|
|
|
|
|
|
|
Reported
|
|
|
Currency
|
|
|
|
|
|
|
|
|
|
|
Increase
|
|
|
Increase
|
|
(Unaudited, U.S. Dollars, in thousands)
|
|
|
2015
|
|
|
2014
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
BioStim
|
|
|
$
|
44,993
|
|
|
$
|
39,739
|
|
|
13.2
|
%
|
|
|
13.2
|
%
|
|
Biologics
|
|
|
|
15,958
|
|
|
|
15,163
|
|
|
5.2
|
%
|
|
|
5.2
|
%
|
|
Extremity Fixation
|
|
|
|
23,931
|
|
|
|
27,673
|
|
|
(13.5
|
)%
|
|
|
(2.2
|
)%
|
|
Spine Fixation
|
|
|
|
19,740
|
|
|
|
17,709
|
|
|
11.5
|
%
|
|
|
11.9
|
%
|
|
Total net sales
|
|
|
$
|
104,622
|
|
|
$
|
100,284
|
|
|
4.3
|
%
|
|
|
7.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales force expansion and an increase in the number of worldwide spine
procedures drove the increase in the Company's BioStim and Biologics
SBUs. The decline in net sales in the Extremity Fixation SBU was largely
due to international challenges, including the strong U.S. dollar
worldwide and restructuring the Company's Brazil subsidiary earlier in
the year. The increase in net sales in the Spine Fixation SBU was
primarily due to reorganizing this SBU, which began in the fourth
quarter of 2014 and included a significant expansion of the U.S. sales
force in 2015.
Gross profit increased $4.4 million to $83.2 million, compared to $78.8
million in the prior year period. Gross margin increased to 79.5%,
compared to 78.6% in the prior year period. The year-over-year increase
in gross margin was driven primarily by an increase in the sales mix of
BioStim and Biologics products, which have a higher gross margin than
the fixation business products.
Total net margin (gross profit less sales and marketing expenses) was
$38.5 million, an increase of 5.6% over $36.5 million in the prior year
period. This improvement was driven by the increase in gross profit.
Operating expenses increased by $0.9 million to $75.8 million, compared
to $74.9 million in the prior year period. This was driven by increases
in sales and marketing expenses and research and development costs,
offset by a decline in restatement and related costs.
Operating income was $7.4 million compared to $4.0 million in the prior
year period.
Adjusted EBITDA, which excludes share-based compensation, foreign
exchange impact, strategic investments, restatements and related costs,
infrastructure investments and legal settlements, increased to $19.3
million or 18.4% of net sales for the fourth quarter, compared to $16.3
million or 16.3% of net sales in the prior year period.
Net income from continuing operations was $2.1 million, or $0.11 per
diluted share, compared to net loss of ($5.1) million, or ($0.27) per
diluted share in the prior year period.
Adjusted net income from continuing operations was $5.3 million, or
$0.28 per diluted share, compared to adjusted net loss of ($0.9)
million, or ($0.05) per diluted share in the prior year period.
As of December 31, 2015, cash and cash equivalents were $63.7 million
compared to $71.2 million (including then restricted cash), as of
December 31, 2014. As of December 31, 2015 the Company had no
outstanding indebtedness and borrowing capacity of $125 million.
Fiscal Year 2015 Financial Results
The following table provides net sales, net sales growth and constant
currency net sales growth by SBU for the year ended December 31,
2015 and 2014:
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Constant
|
|
|
|
|
|
|
|
|
|
|
Reported
|
|
|
Currency
|
|
|
|
|
|
|
|
|
|
|
Increase
|
|
|
Increase
|
|
(Unaudited, U.S. Dollars, in thousands)
|
|
|
2015
|
|
|
2014
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
BioStim
|
|
|
$
|
164,955
|
|
|
$
|
154,676
|
|
|
6.6
|
%
|
|
|
6.7
|
%
|
|
Biologics
|
|
|
|
59,832
|
|
|
|
55,881
|
|
|
7.1
|
%
|
|
|
7.1
|
%
|
|
Extremity Fixation
|
|
|
|
96,034
|
|
|
|
109,678
|
|
|
(12.4
|
)%
|
|
|
1.0
|
%
|
|
Spine Fixation
|
|
|
|
75,668
|
|
|
|
82,042
|
|
|
(7.8
|
)%
|
|
|
(7.3
|
)%
|
|
Total net sales
|
|
|
$
|
396,489
|
|
|
$
|
402,277
|
|
|
(1.4
|
)%
|
|
|
2.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The growth in net sales in the BioStim and Biologics SBUs for the full
year was driven by the expansion of the sales force, increased
productivity from the existing sales force and an increase in the number
of worldwide spine procedures. Despite the headwinds of the
international challenges, including the strong U.S. dollar worldwide and
restructuring the Company's Brazil subsidiary earlier in the year, the
Extremity Fixation SBU grew modestly on a constant currency basis due to
improved performance in Europe and the United States. The full year
decrease in net sales for the Spine Fixation SBU, which had been
expected, was primarily due to reorganizing this SBU in the fourth
quarter of 2014, which negatively impacted the first half of the year
but drove improved results in the fourth quarter of 2015.
Gross profit increased $6.6 million to $310.0 million, compared to
$303.4 million in 2014. Gross margin increased to 78.2%, compared to
75.4% in 2014. The year-over-year increase in gross margin was primarily
driven by an increased sales mix of BioStim and Biologics products,
which have a higher gross margin than the fixation business products.
Total net margin was $131.9 million, a decrease of 3.6% over $136.8
million in 2014. This decline was driven by an increase in sales and
marketing expenses of $11.5 million, offset by improvement in gross
profit of $6.6 million. The increase in sales and marketing expenses was
primarily attributable to an overall increase in the number of sales
managers and field-based training personnel as part of the strategy to
increase the size and improve the productivity of the Company's sales
organizations, as well as sales commission quota overachievement in
certain territories, which, in combination, resulted in an increase in
compensation and commission costs of approximately $6.8 million. The
increase was also attributable to the year-over-year increase in net
sales as well as bad debt expense of $2.0 million taken in response to
the fiscal and economic difficulties experienced by the Commonwealth of
Puerto Rico in late 2015.
Operating expenses increased by $14.5 million to $300.7 million,
compared to $286.2 million in 2014. The increase in operating expenses
was driven by increases to sales and marketing of $11.5 million as
described above, and general and administrative expenses of $8.1
million, offset by a decline in restatements and related costs of $6.5
million. The increase in general and administrative expense was largely
driven by legal settlements totaling $5.3 million in 2015, increased
spending of $1.6 million associated with infrastructure strengthening as
part of Project Bluecore, increased stock compensation expense of $1.5
million, and an increase in professional fees and personnel costs within
the finance department as part of the Company's internal controls
remediation efforts.
Operating income was $9.3 million compared to $17.1 million in 2014.
Adjusted EBITDA, which excludes share-based compensation, foreign
exchange impact, strategic investments, restatements and related costs,
infrastructure investments, legal settlements, gain on sale of assets,
and the Puerto Rico adjustment, decreased to $60.7 million or 15.3% of
net sales for the year, compared to $64.9 million or 16.1% of net sales
in 2014. This decrease was primarily a result of increased investments
in the sales force, increased research and development expenses, and
increased general and administrative costs.
Net loss from continuing operations was ($2.3) million, or ($0.12) per
diluted share, compared to ($3.7) million, or ($0.20) per diluted share
in 2014.
Adjusted net income from continuing operations was $15.0 million, or
$0.79 per diluted share, compared to adjusted net income of $10.2
million, or $0.55 per diluted share in 2014.
Share Repurchase Plan
In the fourth quarter of 2015, the Company announced a share repurchase
plan based on the Company's Board of Directors authorizing the purchase
of up to $75 million of the Company's common stock through the end of
September 2017. The timing of purchases and the number of shares to be
purchased will depend on market conditions and other factors.
Repurchases are expected to consist primarily of open market
transactions at prevailing market prices in accordance with the
guidelines specified under Rule 10b-18 of the Securities Exchange Act of
1934, as amended. As of December 31, 2015, the Company had repurchased
approximately 294,000 shares of common stock for $11.6 million.
Fiscal 2016 Outlook
For the fiscal year ending December 31, 2016, the Company expects the
following results, assuming exchange rates are the same as those
currently prevailing.
|
|
|
|
Year Ending
|
|
|
|
|
December 31, 2016
|
|
Net Sales
|
|
|
$407 million — $412 million1
|
|
Adjusted EBITDA
|
|
|
$67 million — $70 million2
|
|
Adjusted EPS from continuing operations
|
|
|
$1.25 — $1.353
|
|
1 |
|
Represents a year-over-year increase of 2.7% to 3.9% on a reported
basis.
|
|
2 |
|
Represents a year-over-year increase of 10.4% to 15.3% on a
reported basis.
|
|
3 |
|
Represents a year-over-year increase of 19.0% to 28.6% on a pro
forma basis (see Pro forma Adjusted Earnings per Diluted Share
from Continuing Operations table.)
|
|
|
|
|
Conference Call
Orthofix will host a conference call today at 4:30 PM Eastern time to
discuss the Company's financial results for the fourth quarter and full
2015 fiscal year. Interested parties may access the conference call by
dialing (877) 548-7905 in the U.S. and (719) 325-4752 outside the U.S.,
and referencing the conference ID 6432201. A replay of the call will be
available for two weeks by dialing (888) 203-1112 in the U.S. and (719)
457-0820 outside the U.S., and entering the conference ID 6432201. A
webcast of the conference call may be accessed by going to the Company's
website at www.orthofix.com,
by clicking on the Investors link and then the Events and Presentations
page.
About Orthofix
Orthofix International N.V. is a diversified, global medical device
company focused on improving patients' lives by providing superior
reconstructive and regenerative orthopedic and spine solutions to
physicians worldwide. Headquartered in Lewisville, Texas, the Company
has four strategic business units that include BioStim, Biologics,
Extremity Fixation and Spine Fixation. Orthofix products are widely
distributed via the Company's sales representatives, distributors and
its subsidiaries. In addition, Orthofix is collaborating on research and
development activities with leading clinical organizations such as
the Musculoskeletal Transplant Foundation and the Texas Scottish Rite
Hospital for Children. For more information, please visit www.orthofix.com.
Forward-Looking Statements
This communication contains certain forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements
concerning the projections, financial condition, results of operations
and businesses of Orthofix and its subsidiaries, are based on
management's current expectations and estimates and involve risks and
uncertainties that could cause actual results or outcomes to differ
materially from those contemplated by the forward-looking statements.
The forward-looking statements in this release do not constitute
guarantees or promises of future performance. Factors that could cause
or contribute to such differences may include, but are not limited to,
risks relating to: the expected sales of our products, including
recently launched products; the continuation of our ongoing share
repurchase program; an investigation by the Division of Enforcement of
the Securities and Exchange Commission (the "SEC") and related
securities class action litigation arising out of our prior accounting
review and restatements of financial statements; our review of
allegations of improper payments involving our Brazil-based subsidiary;
the geographic concentration of certain of our sales and accounts
receivable in countries or territories that are facing severe fiscal
challenges; unanticipated expenditures; changing relationships with
customers, suppliers, strategic partners and lenders; changes to and the
interpretation of governmental regulations; the resolution of pending
litigation matters (including our indemnification obligations with
respect to certain product liability claims against our former sports
medicine global business unit); our ongoing compliance obligations under
a corporate integrity agreement with the Office of Inspector General of
the Department of Health and Human Services (and related terms of
probation) and a deferred prosecution agreement with the U.S. Department
of Justice; risks relating to the protection of intellectual property;
changes to the reimbursement policies of third parties; the impact of
competitive products; changes to the competitive environment; the
acceptance of new products in the market; conditions of the orthopedic
and spine industry; credit markets and the global economy; corporate
development and market development activities, including acquisitions or
divestitures; unexpected costs or operating unit performance related to
recent acquisitions; and other risks described in the "Risk Factors"
section of our upcoming Annual Report on Form 10-K for the fiscal year
ended December 31, 2015, as well as in other reports that we file in the
future. Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date hereof. The Company undertakes no obligation to update or
revise the information contained in this press release.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ORTHOFIX INTERNATIONAL N.V.
|
|
Condensed Consolidated Statements of Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Year Ended
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
(Unaudited, U.S. Dollars, in thousands, except share and per
share data)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
Product sales
|
|
|
$
|
89,623
|
|
|
|
$
|
86,350
|
|
|
|
$
|
341,084
|
|
|
|
$
|
351,525
|
|
|
Marketing service fees
|
|
|
|
14,999
|
|
|
|
|
13,934
|
|
|
|
|
55,405
|
|
|
|
|
50,752
|
|
|
Net sales
|
|
|
|
104,622
|
|
|
|
|
100,284
|
|
|
|
|
396,489
|
|
|
|
|
402,277
|
|
|
Cost of sales
|
|
|
|
21,411
|
|
|
|
|
21,457
|
|
|
|
|
86,525
|
|
|
|
|
98,912
|
|
|
Gross profit
|
|
|
|
83,211
|
|
|
|
|
78,827
|
|
|
|
|
309,964
|
|
|
|
|
303,365
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing
|
|
|
|
44,720
|
|
|
|
|
42,365
|
|
|
|
|
178,080
|
|
|
|
|
166,547
|
|
|
General and administrative
|
|
|
|
23,734
|
|
|
|
|
23,678
|
|
|
|
|
87,157
|
|
|
|
|
79,074
|
|
|
Research and development
|
|
|
|
7,570
|
|
|
|
|
6,176
|
|
|
|
|
26,389
|
|
|
|
|
24,994
|
|
|
Restatements and related costs
|
|
|
|
(193
|
)
|
|
|
|
2,655
|
|
|
|
|
9,083
|
|
|
|
|
15,614
|
|
|
|
|
|
|
75,831
|
|
|
|
|
74,874
|
|
|
|
|
300,709
|
|
|
|
|
286,229
|
|
|
Operating income
|
|
|
|
7,380
|
|
|
|
|
3,953
|
|
|
|
|
9,255
|
|
|
|
|
17,136
|
|
|
Other income and expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
|
(166
|
)
|
|
|
|
(430
|
)
|
|
|
|
(489
|
)
|
|
|
|
(1,785
|
)
|
|
Other income (expense), net
|
|
|
|
(67
|
)
|
|
|
|
(1,664
|
)
|
|
|
|
(259
|
)
|
|
|
|
(2,895
|
)
|
|
|
|
|
|
(233
|
)
|
|
|
|
(2,094
|
)
|
|
|
|
(748
|
)
|
|
|
|
(4,680
|
)
|
|
Income before income taxes
|
|
|
|
7,147
|
|
|
|
|
1,859
|
|
|
|
|
8,507
|
|
|
|
|
12,456
|
|
|
Income tax expense
|
|
|
|
(5,041
|
)
|
|
|
|
(6,949
|
)
|
|
|
|
(10,849
|
)
|
|
|
|
(16,200
|
)
|
|
Net income (loss) from continuing operations
|
|
|
|
2,106
|
|
|
|
|
(5,090
|
)
|
|
|
|
(2,342
|
)
|
|
|
|
(3,744
|
)
|
|
Discontinued operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations
|
|
|
|
488
|
|
|
|
|
(794
|
)
|
|
|
|
(1,827
|
)
|
|
|
|
(7,157
|
)
|
|
Income tax benefit
|
|
|
|
775
|
|
|
|
|
86
|
|
|
|
|
1,360
|
|
|
|
|
2,364
|
|
|
Net income (loss) from discontinued operations
|
|
|
|
1,263
|
|
|
|
|
(708
|
)
|
|
|
|
(467
|
)
|
|
|
|
(4,793
|
)
|
|
Net income (loss)
|
|
|
$
|
3,369
|
|
|
|
$
|
(5,798
|
)
|
|
|
$
|
(2,809
|
)
|
|
|
$
|
(8,537
|
)
|
|
Net income (loss) per common share—basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) from continuing operations
|
|
|
$
|
0.11
|
|
|
|
$
|
(0.27
|
)
|
|
|
$
|
(0.12
|
)
|
|
|
$
|
(0.20
|
)
|
|
Net income (loss) from discontinued operations
|
|
|
|
0.07
|
|
|
|
|
(0.04
|
)
|
|
|
|
(0.03
|
)
|
|
|
|
(0.26
|
)
|
|
Net income (loss) per common share—basic
|
|
|
$
|
0.18
|
|
|
|
$
|
(0.31
|
)
|
|
|
$
|
(0.15
|
)
|
|
|
$
|
(0.46
|
)
|
|
Net income (loss) per common share—diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) from continuing operations
|
|
|
$
|
0.11
|
|
|
|
$
|
(0.27
|
)
|
|
|
$
|
(0.12
|
)
|
|
|
$
|
(0.20
|
)
|
|
Net income (loss) from discontinued operations
|
|
|
|
0.07
|
|
|
|
|
(0.04
|
)
|
|
|
|
(0.03
|
)
|
|
|
|
(0.26
|
)
|
|
Net income (loss) per common share—diluted
|
|
|
$
|
0.18
|
|
|
|
$
|
(0.31
|
)
|
|
|
$
|
(0.15
|
)
|
|
|
$
|
(0.46
|
)
|
|
Weighted average number of common shares:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
18,823,455
|
|
|
|
|
18,609,844
|
|
|
|
|
18,795,194
|
|
|
|
|
18,459,054
|
|
|
Diluted
|
|
|
|
19,059,779
|
|
|
|
|
18,609,844
|
|
|
|
|
18,795,194
|
|
|
|
|
18,459,054
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ORTHOFIX INTERNATIONAL N.V.
|
|
Condensed Consolidated Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
(Unaudited, U.S. Dollars, in thousands except share and per share
data)
|
|
|
2015
|
|
|
2014 (1)
|
|
Assets
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
$
|
63,663
|
|
|
|
$
|
36,815
|
|
|
Restricted cash
|
|
|
|
—
|
|
|
|
|
34,424
|
|
|
Trade accounts receivable, less allowance for doubtful accounts of
$8,923 and $7,285 at December 31, 2015 and December 31, 2014,
respectively
|
|
|
|
59,839
|
|
|
|
|
61,358
|
|
|
Inventories
|
|
|
|
57,563
|
|
|
|
|
59,846
|
|
|
Prepaid expenses and other current assets
|
|
|
|
31,187
|
|
|
|
|
26,552
|
|
|
Total current assets
|
|
|
|
212,252
|
|
|
|
|
218,995
|
|
|
Property, plant and equipment, net
|
|
|
|
52,306
|
|
|
|
|
48,549
|
|
|
Patents and other intangible assets, net
|
|
|
|
5,302
|
|
|
|
|
7,152
|
|
|
Goodwill |
|
|
|
53,565
|
|
|
|
|
53,565
|
|
|
Deferred income taxes
|
|
|
|
57,306
|
|
|
|
|
55,725
|
|
|
Other long-term assets
|
|
|
|
19,491
|
|
|
|
|
8,970
|
|
|
Total assets
|
|
|
$
|
400,222
|
|
|
|
$
|
392,956
|
|
|
Liabilities and shareholders' equity
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
Trade accounts payable
|
|
|
$
|
16,391
|
|
|
|
$
|
13,223
|
|
|
Other current liabilities
|
|
|
|
65,597
|
|
|
|
|
53,220
|
|
|
Total current liabilities
|
|
|
|
81,988
|
|
|
|
|
66,443
|
|
|
Other long-term liabilities
|
|
|
|
27,923
|
|
|
|
|
26,886
|
|
|
Total liabilities
|
|
|
|
109,911
|
|
|
|
|
93,329
|
|
|
Contingencies
|
|
|
|
|
|
|
|
Shareholders' equity
|
|
|
|
|
|
|
|
Common shares $0.10 par value; 50,000,000 shares authorized;
18,659,696 and 18,611,495 issued and outstanding as of December
31, 2015 and December 31, 2014, respectively
|
|
|
|
1,866
|
|
|
|
|
1,861
|
|
|
Additional paid-in capital
|
|
|
|
232,126
|
|
|
|
|
232,788
|
|
|
Retained earnings
|
|
|
|
62,551
|
|
|
|
|
65,360
|
|
|
Accumulated other comprehensive loss
|
|
|
|
(6,232
|
)
|
|
|
|
(382
|
)
|
|
Total shareholders' equity
|
|
|
|
290,311
|
|
|
|
|
299,627
|
|
|
Total liabilities and shareholders' equity
|
|
|
$
|
400,222
|
|
|
|
$
|
392,956
|
|
|
_____________
|
|
(1)
|
|
Certain deferred tax balances have been reclassified as a result of
the adoption of newly issued accounting standard ASU 2015-17
|
|
|
|
|
|
|
|
|
ORTHOFIX INTERNATIONAL N.V.
Selected Financial Data
Non-GAAP Performance Measures
The following tables in this press release present reconciliations of
net income (loss) from continuing operations and earnings per diluted
share from continuing operations calculated in accordance with U.S.
generally accepted accounting principles ("GAAP") to non-GAAP
performance measures, referred to as "EBITDA," "Adjusted EBITDA,"
"Adjusted net income (loss) from continuing operations," "Adjusted
earnings per diluted share from continuing operations," "Net margin" and
"Free cash flow" that exclude items specified in the tables. A more
detailed explanation of the items excluded from these non-GAAP measures,
as well as why management believes the non-GAAP measures are useful to
them, is included in the Reconciliations of Non-GAAP Performance
Measures section below. Certain calculations for prior periods which
have been previously presented have been conformed to our current
calculation methodology
Adjusted EBITDA
|
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
(Unaudited, U.S. Dollars, in thousands)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
Net income (loss) from continuing operations
|
|
|
$
|
2,106
|
|
|
|
$
|
(5,090
|
)
|
|
|
$
|
(2,342
|
)
|
|
|
$
|
(3,744
|
)
|
|
Interest expense, net
|
|
|
|
166
|
|
|
|
|
430
|
|
|
|
|
489
|
|
|
|
|
1,785
|
|
|
Income tax expense
|
|
|
|
5,041
|
|
|
|
|
6,949
|
|
|
|
|
10,849
|
|
|
|
|
16,200
|
|
|
Depreciation and amortization
|
|
|
|
5,177
|
|
|
|
|
5,785
|
|
|
|
|
20,923
|
|
|
|
|
22,878
|
|
|
EBITDA
|
|
|
$
|
12,490
|
|
|
|
$
|
8,074
|
|
|
|
$
|
29,919
|
|
|
|
$
|
37,119
|
|
|
Share-based compensation
|
|
|
|
1,689
|
|
|
|
|
1,621
|
|
|
|
|
7,214
|
|
|
|
|
5,724
|
|
|
Foreign exchange impact
|
|
|
|
115
|
|
|
|
|
1,326
|
|
|
|
|
3,489
|
|
|
|
|
2,355
|
|
|
Strategic investments
|
|
|
|
258
|
|
|
|
|
347
|
|
|
|
|
1,359
|
|
|
|
|
347
|
|
|
Restatements and related costs
|
|
|
|
(193
|
)
|
|
|
|
2,655
|
|
|
|
|
9,083
|
|
|
|
|
15,614
|
|
|
Infrastructure investments
|
|
|
|
675
|
|
|
|
|
2,312
|
|
|
|
|
5,407
|
|
|
|
|
3,764
|
|
|
Legal settlements
|
|
|
|
4,237
|
|
|
|
|
—
|
|
|
|
|
5,302
|
|
|
|
|
—
|
|
|
Gain on sale of assets
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(3,099
|
)
|
|
|
|
—
|
|
|
Puerto Rico bad debt expense
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
2,024
|
|
|
|
|
—
|
|
|
Adjusted EBITDA
|
|
|
$
|
19,271
|
|
|
|
$
|
16,335
|
|
|
|
$
|
60,698
|
|
|
|
$
|
64,923
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As a % of net sales
|
|
|
|
18.4
|
%
|
|
|
|
16.3
|
%
|
|
|
|
15.3
|
%
|
|
|
|
16.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Net Income (Loss) from Continuing
Operations (Amounts are shown net of tax)
|
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
(Unaudited, U.S. Dollars, in thousands)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
Net income (loss) from continuing operations
|
|
|
$
|
2,106
|
|
|
|
$
|
(5,090
|
)
|
|
|
$
|
(2,342
|
)
|
|
|
$
|
(3,744
|
)
|
|
Foreign exchange impact
|
|
|
|
72
|
|
|
|
|
836
|
|
|
|
|
2,198
|
|
|
|
|
1,484
|
|
|
Strategic investments
|
|
|
|
163
|
|
|
|
|
219
|
|
|
|
|
856
|
|
|
|
|
219
|
|
|
Restatements and related costs
|
|
|
|
(122
|
)
|
|
|
|
1,673
|
|
|
|
|
5,722
|
|
|
|
|
9,836
|
|
|
Infrastructure investments
|
|
|
|
425
|
|
|
|
|
1,457
|
|
|
|
|
3,406
|
|
|
|
|
2,371
|
|
|
Legal settlements
|
|
|
|
2,669
|
|
|
|
|
—
|
|
|
|
|
3,340
|
|
|
|
|
—
|
|
|
Gain on sale of assets
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(1,952
|
)
|
|
|
|
—
|
|
|
Puerto Rico:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bad debt expense
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
2,024
|
|
|
|
|
—
|
|
|
Income tax valuation allowance
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
1,778
|
|
|
|
|
—
|
|
|
Adjusted net income (loss) from continuing operations
|
|
|
$
|
5,313
|
|
|
|
$
|
(905
|
)
|
|
|
$
|
15,030
|
|
|
|
$
|
10,166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Earnings per Diluted Share from
Continuing Operations (Calculations are shown net of tax)
|
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
(Unaudited, per diluted share)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
EPS from continuing operations
|
|
|
$
|
0.11
|
|
|
|
$
|
(0.27
|
)
|
|
|
$
|
(0.12
|
)
|
|
|
$
|
(0.20
|
)
|
|
Foreign exchange impact
|
|
|
|
0.01
|
|
|
|
|
0.04
|
|
|
|
|
0.11
|
|
|
|
|
0.08
|
|
|
Strategic investments
|
|
|
|
0.01
|
|
|
|
|
0.01
|
|
|
|
|
0.05
|
|
|
|
|
0.01
|
|
|
Restatements and related costs
|
|
|
|
(0.01
|
)
|
|
|
|
0.09
|
|
|
|
|
0.30
|
|
|
|
|
0.53
|
|
|
Infrastructure investments
|
|
|
|
0.02
|
|
|
|
|
0.08
|
|
|
|
|
0.18
|
|
|
|
|
0.13
|
|
|
Legal settlements
|
|
|
|
0.14
|
|
|
|
|
—
|
|
|
|
|
0.17
|
|
|
|
|
—
|
|
|
Gain on sale of assets
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(0.10
|
)
|
|
|
|
—
|
|
|
Puerto Rico:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bad debt expense
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
0.11
|
|
|
|
|
—
|
|
|
Income tax valuation allowance
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
0.09
|
|
|
|
|
—
|
|
|
Adjusted EPS from continuing operations
|
|
|
$
|
0.28
|
|
|
|
$
|
(0.05
|
)
|
|
|
$
|
0.79
|
|
|
|
$
|
0.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Margin
|
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
(Unaudited, U.S. Dollars in thousands)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
Gross profit
|
|
|
$
|
83,211
|
|
|
|
$
|
78,827
|
|
|
|
$
|
309,964
|
|
|
|
$
|
303,365
|
|
|
Less: sales and marketing
|
|
|
|
(44,720
|
)
|
|
|
|
(42,365
|
)
|
|
|
|
(178,080
|
)
|
|
|
|
(166,547
|
)
|
|
Total net margin
|
|
|
$
|
38,491
|
|
|
|
$
|
36,462
|
|
|
|
$
|
131,884
|
|
|
|
$
|
136,818
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As a % of net sales
|
|
|
|
36.8
|
%
|
|
|
|
36.4
|
%
|
|
|
|
33.3
|
%
|
|
|
|
34.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Margin by SBU
|
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
(Unaudited, U.S. Dollars, in thousands)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
BioStim
|
|
|
$
|
20,244
|
|
|
|
$
|
16,928
|
|
|
|
$
|
67,878
|
|
|
|
$
|
66,096
|
|
|
Biologics
|
|
|
|
7,701
|
|
|
|
|
7,129
|
|
|
|
|
27,226
|
|
|
|
|
26,629
|
|
|
Extremity Fixation
|
|
|
|
6,886
|
|
|
|
|
9,634
|
|
|
|
|
29,493
|
|
|
|
|
31,586
|
|
|
Spine Fixation
|
|
|
|
3,965
|
|
|
|
|
3,096
|
|
|
|
|
8,547
|
|
|
|
|
14,243
|
|
|
Corporate
|
|
|
|
(305
|
)
|
|
|
|
(325
|
)
|
|
|
|
(1,260
|
)
|
|
|
|
(1,736
|
)
|
|
Total net margin
|
|
|
$
|
38,491
|
|
|
|
$
|
36,462
|
|
|
|
$
|
131,884
|
|
|
|
$
|
136,818
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As a % of net sales
|
|
|
|
36.8
|
%
|
|
|
|
36.4
|
%
|
|
|
|
33.3
|
%
|
|
|
|
34.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Cash Flow
|
|
|
|
Year Ended
December 31,
|
|
(Unaudited, U.S. Dollars, in thousands)
|
|
|
2015
|
|
|
2014
|
|
Net cash provided by operating activities
|
|
|
$
|
43,224
|
|
|
|
$
|
50,958
|
|
|
Less: capital expenditures
|
|
|
|
(27,899
|
)
|
|
|
|
(18,525
|
)
|
|
Free cash flow
|
|
|
$
|
15,325
|
|
|
|
$
|
32,433
|
|
|
|
|
|
|
|
|
|
The following tables present on a pro forma basis the Company's three
and twelve months ended December 31, 2015 and 2014 adjusted net income
from continuing operations and adjusted earnings per diluted share from
continuing operations using an effective tax rate of 38%. The Company's
historical methodology included GAAP income tax expense as reported and
certain adjustments net of a 37% tax rate.
Pro forma Adjusted Net Income from Continuing
Operations
|
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
(Unaudited, U.S. Dollars, in thousands)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
Net income (loss) from continuing operations
|
|
|
$
|
2,106
|
|
|
|
$
|
(5,090
|
)
|
|
|
$
|
(2,342
|
)
|
|
|
$
|
(3,744
|
)
|
|
Income tax expense as reported
|
|
|
|
5,041
|
|
|
|
|
6,949
|
|
|
|
|
10,849
|
|
|
|
|
16,200
|
|
|
Income before income taxes from continuing operations
|
|
|
|
7,147
|
|
|
|
|
1,859
|
|
|
|
|
8,507
|
|
|
|
|
12,456
|
|
|
Foreign exchange impact
|
|
|
|
115
|
|
|
|
|
1,326
|
|
|
|
|
3,489
|
|
|
|
|
2,355
|
|
|
Strategic investments
|
|
|
|
258
|
|
|
|
|
347
|
|
|
|
|
1,359
|
|
|
|
|
347
|
|
|
Restatements and related costs
|
|
|
|
(193
|
)
|
|
|
|
2,655
|
|
|
|
|
9,083
|
|
|
|
|
15,614
|
|
|
Infrastructure investments
|
|
|
|
675
|
|
|
|
|
2,312
|
|
|
|
|
5,407
|
|
|
|
|
3,764
|
|
|
Legal settlements
|
|
|
|
4,237
|
|
|
|
|
—
|
|
|
|
|
5,302
|
|
|
|
|
—
|
|
|
Gain on sale of assets
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(3,099
|
)
|
|
|
|
—
|
|
|
Puerto Rico bad debt expense
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
2,024
|
|
|
|
|
—
|
|
|
Adjusted net income from continuing operations before income taxes
|
|
|
|
12,239
|
|
|
|
|
8,499
|
|
|
|
|
32,072
|
|
|
|
|
34,536
|
|
|
Income tax expense at 38%
|
|
|
|
(4,651
|
)
|
|
|
|
(3,230
|
)
|
|
|
|
(12,187
|
)
|
|
|
|
(13,124
|
)
|
|
Adjusted net income from continuing operations
|
|
|
$
|
7,588
|
|
|
|
$
|
5,269
|
|
|
|
$
|
19,885
|
|
|
|
$
|
21,412
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro forma Adjusted Earnings per Diluted Share
from Continuing Operations
|
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
(Unaudited, per diluted share)
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
EPS from continuing operations
|
|
|
$
|
0.11
|
|
|
|
$
|
(0.27
|
)
|
|
|
$
|
(0.12
|
)
|
|
|
$
|
(0.20
|
)
|
|
Income tax expense as reported
|
|
|
|
0.26
|
|
|
|
|
0.37
|
|
|
|
|
0.57
|
|
|
|
|
0.87
|
|
|
EPS before income taxes from continuing operations
|
|
|
|
0.37
|
|
|
|
|
0.10
|
|
|
|
|
0.45
|
|
|
|
|
0.67
|
|
|
Foreign exchange impact
|
|
|
|
0.01
|
|
|
|
|
0.07
|
|
|
|
|
0.18
|
|
|
|
|
0.12
|
|
|
Strategic investments
|
|
|
|
0.01
|
|
|
|
|
0.02
|
|
|
|
|
0.07
|
|
|
|
|
0.02
|
|
|
Restatements and related costs
|
|
|
|
(0.01
|
)
|
|
|
|
0.14
|
|
|
|
|
0.48
|
|
|
|
|
0.84
|
|
|
Infrastructure investments
|
|
|
|
0.04
|
|
|
|
|
0.12
|
|
|
|
|
0.28
|
|
|
|
|
0.20
|
|
|
Legal settlements
|
|
|
|
0.22
|
|
|
|
|
—
|
|
|
|
|
0.28
|
|
|
|
|
—
|
|
|
Gain on sale of assets
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(0.16
|
)
|
|
|
|
—
|
|
|
Puerto Rico bad debt expense
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
0.11
|
|
|
|
|
—
|
|
|
Adjusted EPS from continuing operations before income taxes
|
|
|
|
0.64
|
|
|
|
|
0.45
|
|
|
|
|
1.69
|
|
|
|
|
1.85
|
|
|
Income tax expense at 38%
|
|
|
|
(0.24
|
)
|
|
|
|
(0.17
|
)
|
|
|
|
(0.64
|
)
|
|
|
|
(0.70
|
)
|
|
Adjusted EPS from continuing operations
|
|
|
$
|
0.40
|
|
|
|
$
|
0.28
|
|
|
|
$
|
1.05
|
|
|
|
$
|
1.15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliations of Non-GAAP Performance Measures
Reconciling Items for Adjusted EBITDA, Adjusted Net Income (loss)
from Continuing Operations and Adjusted Earnings per Diluted Share from
Continuing Operations
-
Shared-based compensation - costs related to the Company's
share-based compensation plans, which include stock options,
restricted stock awards, performance-based restricted stock awards (if
applicable), and the Company's stock purchase plan.
-
Foreign exchange impact - gains and losses related to foreign
exchange transactions.
-
Strategic investments - costs related to the Company's
strategic investments such as our investment in eNeura, Inc.
-
Restatements and related costs - legal, accounting, and other
professional costs related to the Company's accounting review and
restatements through March 2015 and legal fees associated with the
ongoing SEC Investigation and Securities Class Action Complaint and
Brazil subsidiary compliance review.
-
Infrastructure investments - costs associated with our
multi-year process and systems improvement effort, "Bluecore."
-
Legal settlements - settlements the Company has reached related
to lawsuits.
-
Gain on sale of assets - gain on the sale of the Company's
Tempus™ Cervical Plate product line.
-
Puerto Rico- bad debt expense and an income tax valuation
allowance, in response to the fiscal and economic difficulties
experienced by the Puerto Rico Commonwealth in late 2015.
Net Margin
Net margin is a non-GAAP financial measure, which is calculated by
subtracting sales and marketing from gross profit. Net margin is the
primary metric used by the Company's Chief Operating Decision Maker in
managing the Company.
Free Cash Flow
Free cash flow is a non-GAAP financial measure, which is calculated by
subtracting capital expenditures from cash flow from operating
activities. Free cash flow is an important indicator of how much cash is
generated or used by our normal business operations, including capital
expenditures. Management uses free cash flow as a measure of progress on
its capital efficiency and cash flow initiatives.
Constant Currency
Constant currency measures represent actual performance presented based
on foreign currency rates from the comparable, prior-year period, to
present actuals at comparable rates. Constant Currency can be presented
for numerous GAAP measures, but is most commonly used by management to
compare revenues with and without the impact of changes in foreign
currencies. When disclosed, constant currency measures are presented
with the applicable GAAP measure for comparability.
Effective Tax Rate Used in Pro Forma Information
The Company believes presenting the pro forma information using a 38%
effective tax rate is more meaningful than its historical methodology
given that this tax rate reflects management's expectation of its
long-term normalized tax rate, which is based on current tax law and
current expected income. The Company's actual income tax expense will
ultimately be based on its GAAP performance and may differ from the 38%
rate used in the pro forma financial measures due to a variety of
factors, including the jurisdictions in which profits are determined to
be earned and taxed; the resolution of issues arising from tax audits
with various tax authorities; and the ability to realize deferred tax
assets.
Management use of, and economic substance behind, Non-GAAP
Performance Measures
Management uses non-GAAP measures to evaluate performance
period-over-period, to analyze the underlying trends in the Company's
business, to assess its performance relative to its competitors and to
establish operational goals and forecasts that are used in allocating
resources. Management uses these non-GAAP measures as the basis for
assessing the ability of the underlying operations to generate cash. In
addition, management uses these non-GAAP measures to further its
understanding of the performance of the Company's business units.
Material Limitations Associated with the Use of Non-GAAP Measures
The non-GAAP measures used in this press release may have limitations as
analytical tools, and should not be considered in isolation or as a
replacement for GAAP performance measures. Some of the limitations
associated with the use of these non-GAAP performance measures are that
they exclude items that reflect an economic cost to the Company and can
have a material effect on cash flows. Similarly, certain non-cash
expenses such as equity compensation expense does not directly impact
cash flows, but is part of total compensation costs accounted for under
GAAP.
Compensation for Limitations Associated with Use of Non-GAAP Measures
Orthofix compensates for the limitations of its non-GAAP performance
measures by relying upon its GAAP results to gain a complete picture of
the Company's performance. The GAAP results provide the ability to
understand the Company's performance based on a defined set of criteria.
The non-GAAP measures reflect the underlying operating results of the
Company's businesses, which management believes is an important measure
of the Company's overall performance. The Company provides a detailed
reconciliation of the non-GAAP performance measures to their most
directly comparable GAAP measures, and encourages investors to review
this reconciliation.
Usefulness of Non-GAAP Measures to Investors
Orthofix believes that providing non-GAAP measures that exclude certain
items provides investors with greater transparency to the information
used by the Company's senior management in its financial and operational
decision-making. Management believes it is important to provide
investors with the same non-GAAP metrics it uses to supplement
information regarding the performance and underlying trends
of Orthofix's business operations in order to facilitate comparisons to
its historical operating results and internally evaluate the
effectiveness of the Company's operating strategies. Disclosure of these
non-GAAP performance measures also facilitates comparisons
of Orthofix's underlying operating performance with other companies in
its industry that also supplement their GAAP results with non-GAAP
performance measures.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160229006710/en/
Orthofix International N.V.
Mark Quick, 214-937-2924
markquick@orthofix.com
Source: Orthofix International N.V.
News Provided by Acquire Media